Search results for "Adiponectin secretion"

showing 2 items of 2 documents

Obesity, type 2 diabetes and risk of digestive cancer.

2010

The frequency of obesity has been increasing worldwide for 20 years. Many epidemiological studies support a correlation between obesity and increased risk of cancer, particularly digestive cancers in both genders, and gynaecological cancer in women. Currently, about 5% of cancers could be directly related to overweight. Carcinogenesis mechanisms induced by obesity involve insulin resistance, adipokine and angiogenic factor secretions, and inflammation. Experimental and clinical evidence suggest that insulin resistance plays a major role in carcinogenesis. Insulin and non-protein banded IGF-1, whose levels are increased in type 2 diabetes, stimulate cellular growth and inhibit apoptosis. Abn…

Leptinmedicine.medical_specialtySerine Proteinase Inhibitorsmedicine.medical_treatmentAdipokineType 2 diabetesOverweightBioinformaticsGlobal HealthRisk AssessmentBody Mass IndexDiabetes ComplicationsBiological FactorsInsulin resistanceAdipokinesRisk FactorsInternal medicineDiabetes mellitusPlasminogen Activator Inhibitor 1PrevalenceMedicineHumansInsulinAdiponectin secretionObesityInsulin-Like Growth Factor IGastrointestinal NeoplasmsEvidence-Based Medicinebusiness.industryInsulinIncidenceGastroenterologyCancerGeneral Medicinemedicine.diseasePrognosisEndocrinologyAdipose TissueDiabetes Mellitus Type 2MetalloproteasesFrancemedicine.symptomInsulin ResistancebusinessGastroenterologie clinique et biologique
researchProduct

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct